Urinary Incontinence - Pipeline Review, H1 2017

Publisher Name :
Date: 28-Feb-2017
No. of pages: 66
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).

  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Urinary Incontinence - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Urinary Incontinence - Overview
Urinary Incontinence - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Urinary Incontinence - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Urinary Incontinence - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Celogos SA
Cook MyoSite Inc
FemmePharma Global Healthcare Inc
GTx Inc
Innovacell Biotechnologie AG
Ipsen SA
Outpost Medicine Ltd
Pfizer Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Ltd
Urinary Incontinence - Drug Profiles
(mirabegron + solifenacin succinate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abobotulinumtoxina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Ischemic Heart Failure, Gastrointestinal Disorders and Urological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enobosarm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gtx-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICES-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Urinary Incontinence - Dormant Projects
Urinary Incontinence - Discontinued Products
Urinary Incontinence - Product Development Milestones
Featured News & Press Releases
Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
Aug 30, 2011: Innovacell passes a further milestone
Feb 22, 2011: Innovacell makes further progress on product development
Jun 15, 2010: Innovacell Enrolls First Patient In Phase IIb Study Of Urocell For Treatment Of Urinary Incontinence
Oct 31, 2008: Fesoterodine Approved in the U.S
Feb 28, 2007: HRA Pharma Invest An Additional Euro 2.5 M In Cell Therapy Through Its Subsidiary Celogos
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Urinary Incontinence, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Urinary Incontinence - Pipeline by Astellas Pharma Inc, H1 2017
Urinary Incontinence - Pipeline by Celogos SA, H1 2017
Urinary Incontinence - Pipeline by Cook MyoSite Inc, H1 2017
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H1 2017
Urinary Incontinence - Pipeline by GTx Inc, H1 2017
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2017
Urinary Incontinence - Pipeline by Ipsen SA, H1 2017
Urinary Incontinence - Pipeline by Outpost Medicine Ltd, H1 2017
Urinary Incontinence - Pipeline by Pfizer Inc, H1 2017
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Urinary Incontinence - Dormant Projects, H1 2017
Urinary Incontinence - Dormant Projects, H1 2017 (Contd..1), H1 2017
Urinary Incontinence - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Urinary Incontinence, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global Overactive Bladder Treatment Market Research Report 2017
    Published: 09-Nov-2017        Price: US 2900 Onwards        Pages: 115
    This report studies Overactive Bladder Treatment in Global market, especially in North America, Europe, China, Japan, focuses on top manufacturers in global market, with revenue and market share for each manufacturer, covering Astellas Pharma Allergan Pfizer Teva (Activas) Johnson & Johnson Market Segment by Regions, this report splits Global into several key Regions, with consumption, revenue, market share and growth rate of Overactive Bladder T......
  • Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Cystitis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Cystitis which can turn out to be future prospe......
  • Nocturnal Enuresis -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Nocturnal Enuresis - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Nocturnal Enuresis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Nocturnal Enuresis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with......
  • Urinary Incontinence - Market Insights, Epidemiology and Market Forecast -2023-7MM
    Published: 01-Nov-2017        Price: US 4950 Onwards        Pages: 77
    DelveInsight's "Urinary Incontinence - Market Insights, Epidemiology and Market Forecast-2023-7MM" Reports provides an overview of the disease and global market size of the Urinary Incontinence for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 2013-2023. Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage ......
  • Interstitial Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Interstitial Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Interstitial Cystitis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Interstitial Cystitis......
  • Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patter......
  • Bladder Pain - Pipeline Insight, 2017
    Published: 01-Nov-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, " Bladder Pain -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Bladder Pain. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Bladder Pain. This report provides information on the therapeutic development for Bladder Pain, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as disco......
  • Cystitis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Cystitis - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Cystitis for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Cystitis forecasted market share for ten years to 2025 segmented by seven major markets. In addition, the report includes the historical and forecasted epidemiologica......
  • Urinary Incontinence - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Urinary Incontinence - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Urinary Incontinence. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Urinary Incontinence wh......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs